Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | Cost Effectiveness and Resource Allocation

Figure 3

From: Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Figure 3

Forest Plot of studies comparing the effect of treatment with peginterferon-alfa-2a vs standard-dose peginterferon-alfa-2b for genotypes 2/3: Peginterferon-alfa-2a showed higher SVR as compared to peginterferon-alfa-2b: 79.2% vs 73.8% (RR = 1.11, IC 95% 1.01 – 1.22, assuming a fixed-effect model).

Back to article page